MVM Life Science Partners

Type

Venture Capital

Status

Active

Location

Boston, United States

Total investments

70

Average round size

26M

Portfolio companies

50

Rounds per year

2.59

Lead investments

24

Follow on index

0.29

Exits

19

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
Monitoring EquipmentBiotechnologyHealth CareHealth DiagnosticsManufacturingMedical DeviceMedicalPharmaceuticalTherapeuticsBiopharma

Summary

MVM Life Science Partners is the famous VC, which was founded in 1997. The main department of described VC is located in the London. The fund was located in Europe if to be more exact in United Kingdom.

Besides them, we counted 8 critical employees of this fund in our database.

Considering the real fund results, this VC is 20 percentage points more often commits exit comparing to other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. When the investment is from MVM Life Science Partners the average startup value is 50-100 millions dollars. Comparing to the other companies, this MVM Life Science Partners performs on 3 percentage points more the average number of lead investments. The top amount of exits for fund were in 2015. The fund is constantly included in 2-6 investment rounds annually. The important activity for fund was in 2011.

The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight BioVex, Zipline Medical, Wilson Therapeutics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Pharmaceutical, Health Care.

The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the MVM Life Science Partners, startups are often financed by XSeed Capital, Stanmore Medical Investments, Scottish Equity Partners. The meaningful sponsors for the fund in investment in the same round are Novo Holdings, Neomed Management, Index Ventures. In the next rounds fund is usually obtained by Index Ventures, HighCape Partners, Novo Holdings.

Show more

Investor highlights

Industry focus
MedtechBiotech/Life SciencesHealthcareManufacturing

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
70
Lead investments
24
Exits
19
Rounds per year
2.59
Follow on index
0.29
Investments by industry
  • Biotechnology (40)
  • Medical (38)
  • Health Care (36)
  • Medical Device (27)
  • Pharmaceutical (11)
  • Show 37 more
Investments by region
  • United States (37)
  • United Kingdom (15)
  • Switzerland (4)
  • Italy (3)
  • Sweden (1)
  • Show 6 more
Peak activity year
2011
Number of Unicorns
2
Number of Decacorns
2

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
16
Avg. valuation at time of investment
90M
Group Appearance index
0.83
Avg. company exit year
11
Avg. multiplicator
4.75
Strategy success index
0.50

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Aegerion Pharmaceuticals 13 Jun 2006 Biotechnology, Health Care, Therapeutics Early Stage Venture 22M United States, Massachusetts, Cambridge
Bricksave 10 Aug 2016 Crowdfunding, Real Estate Investment Seed 342K England, London, United Kingdom
Spherics 12 May 2005 Health Care, Medical, Therapeutics Late Stage Venture 26M

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.